Eton Pharmaceuticals (NASDAQ:ETON) Releases Quarterly Earnings Results, Beats Expectations By $0.28 EPS

Posted by Francis Steltz on Aug 13th, 2026

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.28, FiscalAI reports. The business had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.

Eton Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ:ETON traded down $0.78 during midday trading on Thursday, reaching $40.80. The company’s stock had a trading volume of 568,966 shares, compared to its average volume of 396,114. Eton Pharmaceuticals has a fifty-two week low of $14.27 and a fifty-two week high of $50.18. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The firm has a 50 day moving average price of $38.23 and a two-hundred day moving average price of $28.20. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -582.77 and a beta of 0.86.

Insider Buying and Selling

In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the transaction, the insider directly owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. The trade was a 43.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several large investors have recently bought and sold shares of ETON. Quarry LP bought a new position in shares of Eton Pharmaceuticals in the third quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd purchased a new stake in Eton Pharmaceuticals in the 4th quarter worth about $44,000. Legal & General Group Plc bought a new stake in shares of Eton Pharmaceuticals in the second quarter valued at approximately $41,000. New York State Common Retirement Fund bought a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $115,000. Finally, State of Wyoming lifted its holdings in Eton Pharmaceuticals by 50.0% during the 4th quarter. State of Wyoming now owns 8,161 shares of the company’s stock worth $138,000 after purchasing an additional 2,721 shares in the last quarter. 27.86% of the stock is currently owned by institutional investors.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, implying potential upside from recent trading levels. The analyst still expects Eton’s earnings to grow substantially over time, reaching $6.53 per share in 2030. HC Wainwright analyst coverage
Neutral Sentiment: HC Wainwright projected a progression in annual EPS from $0.52 in 2026 to $1.28 in 2027, $2.23 in 2028, $4.25 in 2029 and $6.53 in 2030. The estimates suggest continued long-term growth, but they are below the firm’s previous forecasts. Eton Pharmaceuticals earnings estimates
Neutral Sentiment: Reported short-interest data showed zero shares sold short as of August 11, unchanged from the prior period. However, the figures appear anomalous and provide little meaningful information about current trading pressure. Eton Pharmaceuticals short interest
Negative Sentiment: HC Wainwright cut its FY2026 EPS estimate to $0.52 from $0.68 and reduced quarterly forecasts for Q2 2026 to $0.11 from $0.15, Q3 to $0.17 from $0.23 and Q4 to $0.19 from $0.25. The firm also lowered its FY2027 EPS estimate to $1.28 from $1.83, FY2028 to $2.23 from $3.50, FY2029 to $4.25 from $5.85 and FY2030 to $6.53 from $8.65. These sizable reductions signal a more cautious view of Eton’s future profitability and may weigh on the shares. HC Wainwright estimate reductions

Analysts Set New Price Targets

Several brokerages have commented on ETON. Zacks Research downgraded Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum raised their price objective on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. HC Wainwright lifted their price objective on Eton Pharmaceuticals from $57.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Canaccord Genuity Group began coverage on Eton Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, Eton Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $54.50.

Read Our Latest Analysis on Eton Pharmaceuticals

About Eton Pharmaceuticals

(Get Free Report)

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.